Literature DB >> 11768734

Combined primary aldosteronism and preclinical Cushing's syndrome: an unusual case presentation of adrenal adenoma.

T Honda1, T Nakamura, Y Saito, Y Ohyama, H Sumino, M Kurabayashi.   

Abstract

A 55-year-old woman was referred to our institution for evaluation of elevated plasma creatine phosphokinase, hypokalemia and hypertension. Her chief complaints were muscle weakness and polyuria. A left adrenal mass, 4 cm in diameter, was noted on computed tomography. Hormonal assessment demonstrated markedly elevated plasma aldosterone concentration, markedly low plasma renin activity, an abnormal diurnal variation in serum cortisol levels, suppressed baseline plasma adrenocorticotrophic hormone, and non-suppression of serum cortisol by dexamethasone suppression test. She showed no symptoms or signs suggestive of Cushing's syndrome. Adrenal scintigraphy with 131I-6-beta-iodomethyl-norcholesterol showed uptake on the left adrenal and inhibition of the contralateral adrenal gland. She was diagnosed with combined primary aldosteronism and preclinical Cushing's syndrome. Cases of combined primary aldosteronism and preclinical Cushing's syndrome are extremely rare. In patients with large aldosterone-producing adenoma, contralateral adrenal insufficiency should be anticipated after the removal of the tumor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768734     DOI: 10.1291/hypres.24.723

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  7 in total

1.  Coexistence of three distinct adrenal tumors in the same adrenal gland in a patient with primary aldosteronism and preclinical Cushing's syndrome.

Authors:  Takafumi Okura; Ken-ichi Miyoshi; Sanae Watanabe; Mie Kurata; Jun Irita; Seiko Manabe; Tomikazu Fukuoka; Jitsuo Higaki; Hironobu Sasano
Journal:  Clin Exp Nephrol       Date:  2006-06       Impact factor: 2.801

2.  Primary aldosteronism and hypercortisolism due to bilateral functioning adrenocortical adenomas.

Authors:  Kenji Oki; Kiminori Yamane; Yu Sakashita; Nozomu Kamei; Hiroshi Watanabe; Naoyuki Toyota; Masanobu Shigeta; Hironobu Sasano; Nobuoki Kohno
Journal:  Clin Exp Nephrol       Date:  2008-06-10       Impact factor: 2.801

3.  Primary Aldosteronism and ARMC5 Variants.

Authors:  Mihail Zilbermint; Paraskevi Xekouki; Fabio R Faucz; Annabel Berthon; Alexandra Gkourogianni; Marie Helene Schernthaner-Reiter; Maria Batsis; Ninet Sinaii; Martha M Quezado; Maria Merino; Aaron Hodes; Smita B Abraham; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Adam Davis; Samson Y Gebreab; Ryan Neff; Electron Kebebew; Jérôme Bertherat; Maya B Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-03-30       Impact factor: 5.958

4.  Difficult-to-control hypertension due to bilateral aldosterone-producing adrenocortical microadenomas associated with a cortisol-producing adrenal macroadenoma.

Authors:  R Morimoto; M Kudo; O Murakami; K Takase; S Ishidoya; Y Nakamura; T Ishibashi; S Takahashi; Y Arai; T Suzuki; H Sasano; S Ito; F Satoh
Journal:  J Hum Hypertens       Date:  2010-05-13       Impact factor: 3.012

5.  Clinical Characteristics of Aldosterone- and Cortisol-Coproducing Adrenal Adenoma in Primary Aldosteronism.

Authors:  Lu Tang; Xintao Li; Baojun Wang; Xin Ma; Hongzhao Li; Yu Gao; Liangyou Gu; Wenyuan Nie; Xu Zhang
Journal:  Int J Endocrinol       Date:  2018-03-25       Impact factor: 3.257

6.  THYMIC CARCINOID WITH ADRENOCORTICOTROPIC HORMONE-PRODUCING ECTOPIC CUSHING SYNDROME AND EMPTY SELLA.

Authors:  Artak Labadzhyan; Se-Min Kim; Jane Rhyu; Takako Araki; Ali Mahtabifard; Shlomo Melmed
Journal:  AACE Clin Case Rep       Date:  2018-05-01

7.  Concurrence of overt Cushing's syndrome and primary aldosteronism accompanied by aldosterone-producing cell cluster in adjacent adrenal cortex: case report.

Authors:  Yoshiro Fushimi; Fuminori Tatsumi; Junpei Sanada; Masashi Shimoda; Shinji Kamei; Shuhei Nakanishi; Kohei Kaku; Tomoatsu Mune; Hideaki Kaneto
Journal:  BMC Endocr Disord       Date:  2021-08-12       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.